Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1Phase 1 1

Status

Unknown 2Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3

Conditions

Breast Neoplasms 285Lymphoma 201Lymphoma, Large B-Cell, Diffuse 167Sarcoma 141Precursor Cell Lymphoblastic Leukemia-Lymphoma 109Hodgkin Disease 85Lymphoma, Non-Hodgkin 78Burkitt Lymphoma 67Lymphoma, Follicular 61Leukemia 58Ovarian Neoplasms 50Neoplasms 50Triple Negative Breast Neoplasms 49Lymphoma, Mantle-Cell 48Multiple Myeloma 47Neuroblastoma 44Carcinoma, Hepatocellular 44Neoplasm Metastasis 41Lymphoma, B-Cell 33Lymphoma, Large-Cell, Anaplastic 31Lymphoma, T-Cell, Peripheral 27Recurrence 26Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 25Osteosarcoma 25Liposarcoma 25Leiomyosarcoma 25Urinary Bladder Neoplasms 23Lymphoma, Large-Cell, Immunoblastic 23Liver Neoplasms 22Endometrial Neoplasms 21

Interventions

Doxorubicin 3lentiviral minigene vaccine of COVID-19 coronavirus 1eltrombopag 1camrelizumab 1apatinib 1Vinorelbine 1Trabectedin 1Temozolomide 1Sodium Chloride 1Methotrexate 1Irinotecan 1FANG vaccine 1Dexamethasone 1Cisplatin 1Adrenal Cortex Hormones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Neoplasms, Connective and Soft Tissue × Doxorubicin × Clear all
NCT05057130 2024-04-01

Neoadjuvant Combination of Doxorubicin, Cisplatin and Methotrexate in Patients Aged 24-40 Years With Primary Bone Tumors

Blokhin's Russian Cancer Research Center

Phase 2/3 Unknown
50 enrolled
Sarcoma

Bone Neoplasms, Neoplasms, Connective Tissue, Sarcoma, Osteosarcoma, Neoplasms, Connective and Soft Tissue

NCT04910126 2021-06-02

Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2 Unknown
84 enrolled
Sarcoma

Sarcoma, Neoplasms, Connective and Soft Tissue

NCT00102609 2013-01-10

A Safety Study Utilizing Yondelis and Doxorubicin in Patients With a Type of Cancer Called Soft Tissue Sarcoma

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 1 Completed
41 enrolled
Sarcoma

Neoplasms, Neoplasms by Histologic Type, Sarcoma, Neoplasms, Connective and Soft Tissue

Data powered by HemOnc (CC BY 4.0) Colophon âš¡